Literature DB >> 36176368

Reversible Pulmonary Arterial Hypertension Induced by Dasatinib.

Hsiu-Chuan Lee1, Chi-Cheng Huang2.   

Abstract

Entities:  

Year:  2022        PMID： 36176368      PMCID： PMC9479055          DOI： 10.6515/ACS.202209_38(5).20220330B

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN： 1011-6842            Impact factor:   1.800


× No keyword cloud information.
  10 in total

1.  Echocardiography for Evaluation of Oncology Therapy-Related Cardiotoxicity.

Authors:  Chun-Li Wang; Pao-Hsien Chu
Journal:  Acta Cardiol Sin       Date:  2016-09       Impact factor: 2.672

2.  2018 TSOC guideline focused update on diagnosis and treatment of pulmonary arterial hypertension.

Authors:  Wei-Chun Huang; Chih-Hsin Hsu; Shih-Hsien Sung; Wan-Jing Ho; Chun-Yuan Chu; Chih-Ping Chang; Yu-Wei Chiu; Chun-Hsien Wu; Wei-Ting Chang; Lin Lin; Shoa-Lin Lin; Chin-Chang Cheng; Yih-Jer Wu; Shu-Hao Wu; Tsu-Yi Hsieh; Hsao-Hsun Hsu; Morgan Fu; Zen-Kong Dai; Ping-Hung Kuo; Juey-Jen Hwang; Shu-Meng Cheng
Journal:  J Formos Med Assoc       Date:  2019-03-26       Impact factor: 3.282

3.  Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study.

Authors:  Jason Weatherald; Marie-Camille Chaumais; Laurent Savale; Xavier Jaïs; Andrei Seferian; Matthieu Canuet; Hélène Bouvaist; Pascal Magro; Anne Bergeron; Christophe Guignabert; Olivier Sitbon; Gérald Simonneau; Marc Humbert; David Montani
Journal:  Eur Respir J       Date:  2017-07-27       Impact factor: 16.671

4.  Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.

Authors:  Christophe Guignabert; Carole Phan; Andrei Seferian; Alice Huertas; Ly Tu; Raphaël Thuillet; Caroline Sattler; Morane Le Hiress; Yuichi Tamura; Etienne-Marie Jutant; Marie-Camille Chaumais; Stéphane Bouchet; Benjamin Manéglier; Mathieu Molimard; Philippe Rousselot; Olivier Sitbon; Gérald Simonneau; David Montani; Marc Humbert
Journal:  J Clin Invest       Date:  2016-08-02       Impact factor: 14.808

5.  First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension.

Authors:  Cécile Daccord; Igor Letovanec; Patrick Yerly; Jonathan Bloch; Adam Ogna; Laurent P Nicod; John-David Aubert
Journal:  Eur Respir J       Date:  2018-03-01       Impact factor: 16.671

Review 6.  Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.

Authors:  Neil P Shah; Nicola Wallis; Harrison W Farber; Michael J Mauro; Robert A Wolf; Daniele Mattei; Mausumee Guha; Delphine Rea; Andrew Peacock
Journal:  Am J Hematol       Date:  2015-10-12       Impact factor: 10.047

7.  Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.

Authors:  Jorge E Cortes; Giuseppe Saglio; Hagop M Kantarjian; Michele Baccarani; Jiří Mayer; Concepción Boqué; Neil P Shah; Charles Chuah; Luis Casanova; Brigid Bradley-Garelik; George Manos; Andreas Hochhaus
Journal:  J Clin Oncol       Date:  2016-05-23       Impact factor: 44.544

8.  Haemodynamic definitions and updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; David Montani; David S Celermajer; Christopher P Denton; Michael A Gatzoulis; Michael Krowka; Paul G Williams; Rogerio Souza
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

9.  EXPRESS: Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors.

Authors:  Ashraf El-Dabh; Deepak Acharya
Journal:  Pulm Circ       Date:  2019-07-05       Impact factor: 3.017
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.